Abstract 789P
Background
PIK3CA mutations are among the most frequent alterations in solid tumors. However, monotherapy with PI3Kα inhibitors has shown only modest efficacy for PIK3CA-mutated cancers, with an objective response rate (ORR) of less than 10%. Novel biomarkers of greater predictive value is needed. Meanwhile, genome-wide CRISPR/Cas9 screening indicated that cell lines with concurrent ARID1A and PIK3CA mutations showed exceptional dependency on PIK3CA, suggesting the co-mutation may serve as predictive biomarker in developing PI3Kα inhibitors. WX390 is a highly potent PI3Kα/mTOR dual inhibitor currently under clinical development in solid tumors.
Methods
Preclinical in vitro and in vivo models were utilized for inquiry of the efficacy of WX390 in PIK3CA and ARID1A co-mutants. We initiated a multicenter, open label, and single arm phase 2 trial of WX390 monotherapy in patients (pts) with platinum resistant ovarian clear cell carcinoma (OCCC) carrying PIK3CA mutation. WX390 was administered orally daily at 1.1mg qd.
Results
Co-occurence of PIK3CA and ARID1A mutation is a significant genetic event across human cancers (data from TCGA and MSK cohorts, N=51,561, Log2 odds ratio=1.556, χ2 P < 0.001). Co-mutation of ARID1A occurs in 18% of pts with PIK3CA mutations in pan-cancer, and 65.7% of pts with PIK3CA-mutated OCCC. The preclinical models with concurrent ARID1A and PIK3CA mutations showed more sensitive to WX390 treatment. Clinical efficacy of WX390 was shown in PIK3CA mutated platinum resistant OCCC. As of March 29, 2024, among the 17 efficacy-evaluable pts, the ORR was 30% (PIK3CAmut-ARID1Amut pts, N=3/10) vs 14.3% (PIK3CAmut-ARID1Awt pts, N=1/7). The 48-week PFS rate was 40% (PIK3CAmut-ARID1Amut pts) vs 14.3% (PIK3CAmut-ARID1Awt pts). The most common treatment related adverse events included hyperglycemia, diarrhea, and fatigue, similar to those reported with other PI3Kα inhibitors.
Conclusions
Co-occurring PIK3CAmut- ARID1Amut is highly prevalent in human cancers and may indicate enhanced response to WX390. WX390 had a manageable safety profile and encouraging efficacy in platinum resistant OCCC pts, especially for the PIK3CAmut- ARID1Amut sub-group. Further evaluation of efficacy and safety are ongoing.
Clinical trial identification
NCT06117540.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
870P - POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Presenter: Martin Forster
Session: Poster session 02
871P - Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
Presenter: Lara Iglesias Docampo
Session: Poster session 02
873P - Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA
Presenter: Andreas Dietz
Session: Poster session 02
874P - Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Ye Guo
Session: Poster session 02
875P - A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Dongmei Ji
Session: Poster session 02
876P - Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Xiaozhong Chen
Session: Poster session 02
878P - Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Presenter: Anthony Kong
Session: Poster session 02
879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jared Weiss
Session: Poster session 02